Contributions
Abstract: EP1707
Type: Poster Sessions
Abstract Category: Therapy - Others
Objectives: When Prevalence of multiple sclerosis in a high population country like Egypt was found to be 1.41%, from all neurological disorders the challenges on government &society will increase due to scarcity of resources and priority issues Although interferon beta (IFNβ) have been shown to reduce the risk for disease progression for MS therefor Treatment adherence is essential for enhancement patients outcomes.
The objective of this research is closing the gaps for treatment adherence policy to enhance patient's outcomes and efficient utilization of resources.
Methods: Developing patent support program (PSP) for MS patients this program includes (training injection - patient counseling from clinical pharmacist - follow up visits based medical file for the patients - fixed telephone number for any inquiries about the disease from the patients was created )
Time horizon for the assessment of the program was 12 months SF36 questioner was used for evaluating impact of the program on quality of life. Direct medical and in direct medical costs was calculated for evaluation of utilization of health care resources. Data from aged (18 -60) for 1 year was analyzed.
Results: With 200 number of patients (mean age: 33, 66.7 % female) after 12 months cost of treatment per patient was reduced with percentage (50%) the annual relapse rate was reduced by 65 % Total medical cost of relapse was discounted by( 50 % )
Conclusion: Creating an effective patent support program (PSP) focusing on reducing patent's adherence may enhance outcomes for MS patients and efficient resources utilization.
Disclosure: i have no conflict of intrest
Abstract: EP1707
Type: Poster Sessions
Abstract Category: Therapy - Others
Objectives: When Prevalence of multiple sclerosis in a high population country like Egypt was found to be 1.41%, from all neurological disorders the challenges on government &society will increase due to scarcity of resources and priority issues Although interferon beta (IFNβ) have been shown to reduce the risk for disease progression for MS therefor Treatment adherence is essential for enhancement patients outcomes.
The objective of this research is closing the gaps for treatment adherence policy to enhance patient's outcomes and efficient utilization of resources.
Methods: Developing patent support program (PSP) for MS patients this program includes (training injection - patient counseling from clinical pharmacist - follow up visits based medical file for the patients - fixed telephone number for any inquiries about the disease from the patients was created )
Time horizon for the assessment of the program was 12 months SF36 questioner was used for evaluating impact of the program on quality of life. Direct medical and in direct medical costs was calculated for evaluation of utilization of health care resources. Data from aged (18 -60) for 1 year was analyzed.
Results: With 200 number of patients (mean age: 33, 66.7 % female) after 12 months cost of treatment per patient was reduced with percentage (50%) the annual relapse rate was reduced by 65 % Total medical cost of relapse was discounted by( 50 % )
Conclusion: Creating an effective patent support program (PSP) focusing on reducing patent's adherence may enhance outcomes for MS patients and efficient resources utilization.
Disclosure: i have no conflict of intrest